higher (1), the current study (9) reports a rate of 3.8%.
very late periods after PCI (4) (5) (6) (7) (8) . In this issue of JACC: Cardiovascular Interventions, Waksman et al. (9) present the DESERT (Drug-Eluting Stent Event Registry of Thrombosis) study in which they set out to Dr. Galper has received research grant support from the National
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I S S N 1 9 3 6 -8 7 9 8 / $ 3 6 . 0 0 study (9) or the study by Armstrong et al. (7) because they would not reach angiography, and as a result, mortality rates were likely underestimated.
To have an impact on clinical care, a study to examine risk factors should provide assessment of which factors might be modified to decrease risk. Two key treatment choices in this regard are stent type and antiplatelet regimen. Regarding DES type, the investigators observed no effect between earlier and later designs despite randomized trials supporting lower late ST rates for current DES compared with prior designs (6, 10, 11) . Limitations of the available data might be the cause of this discrepancy from randomized trial data. First, lack of power (<10% of subjects received newer DES), and second, the method used for selecting cases and controls may have undermined the ability to examine effects of stent choice. Because stent type is segregated by calendar time and institution (e.g., which stents were prevalent in an institution on a given day), matching cases and controls on site 
